WCLC 2021 | Driving CAR-T forwards for solid tumors

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, discusses the development of immune effector cell therapies, in particular chimeric antigen receptor (CAR)-T cell therapies, for the treatment of solid tumors. Dr Johnson discusses the challenge of identifying targets for these therapies and the need to overcome difficulties around recruiting patients for trials by improving screening strategies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).